Company news
Cue Biopharma, Inc. (NASDAQ:CUE) news
Every Cue Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
June 15, 2020
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
May 19, 2020
Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University
May 14, 2020
Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer
April 20, 2020
Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
March 17, 2020
Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
January 21, 2020
Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 12, 2019
Cue Biopharma to Present at Upcoming Investor Conferences in November 2019
November 6, 2019
Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
October 30, 2019
Cue Biopharma Announces Changes to its Board of Directors
October 9, 2019
Cue Biopharma Promotes Dr. Anish Suri to President and CSO
October 7, 2019
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
September 30, 2019